Avelumab plus axitinib in unresectable or metastatic type B3 thymomas and thymic carcinomas (CAVEATT): a single-arm, multicentre, phase 2 trial
Articolo
Data di Pubblicazione:
2022
Abstract:
Patients with advanced type B3 thymoma and thymic carcinoma resistant to chemotherapy have few treatment options. We report the efficacy and safety results of the combination of the anti-PD-L1 inhibitor avelumab with the anti-angiogenesis drug axitinib in patients with advanced type B3 thymoma and thymic carcinoma.
Tipologia CRIS:
1.1 Articolo in rivista
Elenco autori:
Conforti, Fabio; Zucali, Paolo Andrea; Pala, Laura; Catania, Chiara; Bagnardi, Vincenzo; Sala, Isabella; Della Vigna, Paolo; Perrino, Matteo; Zagami, Paola; Corti, Chiara; Stucchi, Sara; Barberis, Massimo; Guerini-Rocco, Elena; Di Venosa, Benedetta; De Vincenzo, Fabio; Cordua, Nadia; Santoro, Armando; Giaccone, Giuseppe; Martino De Pas, Tommaso
Link alla scheda completa:
Pubblicato in: